Clinical Trials
9 trialsNCT01318642 2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
NantBioScience, Inc.
Phase 2 Terminated
NCT00807612 2024-09-25
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT00819169 2024-08-20
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Phase 1/2 Terminated
NCT04129151 2024-08-01
Palbociclib + Ganitumab In Ewing Sarcoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01562899 2020-12-10
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01708161 2018-09-13
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis
Phase 1/2 Terminated
NCT00718523 2016-01-12
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Translational Research in Oncology
Phase 2 Terminated